The present invention relates to the treatment of androgen receptor positive breast cancer in a subject, for example a female subject. Accordingly, the invention includes a method of treating a subject comprising administering to a subject a therapeutically effective amount of a SARM compound of the invention, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) a method of treating a subject suffering from breast cancer, b) a method of treating a subject suffering from metastatic breast cancer, c) a method of treating a subject suffering from refractory breast cancer, d) a method of treating a subject suffering from AR positive breast cancer, e) A method of treating a subject suffering from refractory breast cancer, f) a method of treating a subject suffering from AR positive metastatic breast cancer, g) a method of treating a subject suffering from AR positive and ER positive breast cancer, h) (i) treatment of patients with advanced breast cancer； (j) treatment of patients with advanced breast cancer, such as SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado- K) treatment of metastasis in a subject suffering from breast cancer, prevention and / or prevention of metastatic disease in a subject suffering from breast cancer who have failed breast cancer treatment, , A method of inhibiting or inhibiting l) a method of prolonging the survival of breast cancer subjects, and / or m) a method of prolonging the progression-free survival of breast cancer subjects.본 발명은 대상자, 예를 들어, 여성 대상자의 안드로겐 수용체 양성 유방암의 치료에 관한 것이다. 따라서, 본 발명은 치료적으로 유효한 양의 선택적 안드로겐 수용체 조절자(SARM) 화합물을 대상자에 투여하는 단계를 포함하는, 치료적으로 유효한 양의 본 발명의 SARM 화합물을 대상자에 투여하는 단계를 포함하는, a) 유방암을 앓는 대상자의 치료방법, b) 전이성 유방암을 앓는 대상자의 치료방법, c) 불응성 유방암을 앓는 대상자의 치료방법, d) AR 양성 유방암을 앓는 대상자의 치료방법, e) AR 양성 불응성 유방암을 앓는 대상자의 치료방법, f) AR 양성 전이성 유방암을 앓는 대상자의 치료방법, g) AR 양성 및 ER 양성 유방암을 앓는 대상자의 치료방법, h) 삼중 음성 유방암을 앓는 대상자의 치료방법, i) 진행된 유방암을 앓
